ESR1 and breast carcinoma: It is notable that DLG5 expression is down‐regulated in CD44+/CD24− BCSCs.11 Our previous study and those of others have revealed that DLG5 silencing promotes the process of epithelial‐to‐mesenchymal transition (EMT) and stemness of ER+ breast cancer cells by inhibiting the Hippo signalling.5, 10, 12 However, how DLG5 regulates the stemness of breast cancer cells and TAM resistance has not been clarified.